Bridgehead International voted Strategic Advisor of the Year - Healthcare

Bridgehead International is pleased to announce that it has been voted UK Strategic Advisor of the Year – Healthcare in the ACQ Finance Magazine Awards for 2009.

Bridgehead CEO, Timothy Fitzgerald commented, 'At this time of economic constraint it is even more critical that companies seek and take the best advice; we consider awards such as this confirm that we are delivering what our clients need to drive their businesses forward.'

Bridgehead is a leading bio-pharmaceutical consultancy group, providing a range of services designed to assist clients in achieving extraordinary growth across the product and technology value chain. Bridgehead's mission is to work with commercial organisations, government agencies and the investment community to ensure that:

Companies have the funding, structure and strategic focus to deliver high levels of innovation and financial return

Patients have rapid and broad access to new innovative medicines, medical devices and diagnostic tools, particularly in areas of high unmet need.

Bridgehead International works for a broad spectrum of life science companies, academic groups and financial institutions and has established a track record of success over the past 15 years. Published examples of our work are the independent experts' reports prepared to support fund raising via the London Stock Exchange, UK Alternative Investment Market and other public stock markets.

Recent assignments have included:

  • Due diligence and commercial forecasting to support a >$50 million royalty stream acquisition for an established specialist pharmaceutical product
  • Independent due diligence and valuation to support a major fund raising initiative for five medical device companies Initial valuation, prior to due diligence on an Italian pharmaceutical acquisition target
  • Commercial due diligence on a >$200 million pharmaceutical pharmaceutical portfolio prior to acquisition
  • Independent commercial due diligence on a >$350 million European pharmaceutical acquisition
  • Pricing, reimbursement and market access due diligence on acquisition targets in the following therapy areas:
    • Cardiovascular
    • Dermatology
    • Diabetes
    • Hepatitis C
    • Medical aesthetics
    • Metabolism
    • Multiple sclerosis
    • Oncology
    • Respiratory orphan drug
    • Rheumatoid arthritis